Please login to the form below
tenofovir alafenamide
This page shows the latest tenofovir alafenamide news and features for those working in and with pharma, biotech and healthcare.
Gilead’s Biktarvy gets European approval, setting up battle with GSK
The single tablet regimen (STR) is a combination of integrase inhibitor bictegravir with Gilead’s already blockbuster Descovy, a combination of emtricitabine (FTC) and tenofovir alafenamide (TAF).
Latest news
-
The year of the blockbuster
Biktarvy (tenofovir alafenamide emtricitabine bictegravir) from Gilead:Gilead’s HIV triplet comprising the nucleoside reverse transcriptase inhibitor tenofovir alafenamide, the nucleoside reverse transcriptase inhibitor emtricitabine and the novel
-
Daily Brief: AI to boost early NHS cancer diagnosis, AZ shareholder revolt, Juluca approval
However Gilead has its own direct competitor, Biktarvy combines the novel integrase inhibitor bictegravir with Gilead's Descovy, a combo of emtricitabine and tenofovir alafenamide.
-
CHMP backs first-line use for AZ’s Tagrisso in lung cancer
There was also good news at the CHMP meeting for Gilead Sciences’HIV division, with the panel giving its blessing to three-drug, fixed-dose therapy Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide).
-
Morning brief: Allergan’s migraine results, Biktarvy approved in Europe and more
Gilead’s HIV drug Biktarvy recommended in Europe. On Friday Europe’s CHMP recommended a marketing authorisation for Gilead’s new HIV treatment Biktarvy (bictegravir/emtricitabine/tenofovir alafenamide).
-
ViiV’s two-drug HIV combo backed by CHMP
Its main rival is expected to be Gilead’s new fixed-dose regimen Biktarvy, which combines integrase inhibitor bictegravir with the two ingredients in its fast-growing Descovy (emtricitabine/tenofovir alafenamide)
More from news
Approximately 4 fully matching, plus 29 partially matching documents found.
Latest Intelligence
-
Choices, choices: the rapidly evolving HIV treatment landscape
With Triumeq signalling the approval of the first STR without tenofovir disoproxil fumarate (TDF) it can, uniquely, be used in those patients with impaired kidney function. ... Gilead, in hot pursuit, is in phase III of development of a new regimen where
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
Featured jobs
- Home based, Chief Medical Writer, Medical Communications
-
Excellent package
- Head of Market Access - International - Based Cambridge
-
Excellent Basic, Bonus and Flex Benefits
- Home based, Principal Medical Writer, Medical Communications
-
Excellent package
-
Account Manager
-
£40, 000 - £45, 000 benefits
-
Senior Account Manager
-
Competitive salary commensurate with experience
- Home based, Senior Medical Writer, Medical Communications
-
Excellent package
- Account Director, Consumer Healthcare PR, Global PR agency
-
£50, 000 – £58, 000
- Home based, Editorial Team Leader, Medical Communications
-
Excellent package
- Strategic Planner, Healthcare Advertising
-
£47, 000 – £53, 000
-
Client Services Director - Med Comms
-
Great salary and bebefits
- Principal Medical Writer / Editorial Director – Medical Communic...
-
£60, 000 - £80, 000
- Senior Project Manager - Medical Writing
-
Great salary and bebefits
- Senior Medical Writer, Healthcare Advertising Agency
-
£45, 000 – £50, 000
- Account Director, Medical Communications
-
C£50 – 65, 000 benefits and bonus
- Business Unit Head, Medical Communications, London
-
Excellent package
- Multi-Channel Account Managers - Road / Homebased – Full or Part...
-
Competitive salary
Subscribe to our email news alerts
- Communiqué Awards 2018: Photo Gallery - Communiqué Awards 2016
- NHS England says yes to Roche's Hemlibra
- Moving annual total (MAT)
- Vertex to Theresa May: Orkambi verdict ‘threatens bio investment’
- GSK sells eczema and psoriasis drug to Dermavant for £250m
- Communiqué Awards 2018: Winners in pictures - Communiqué Awards 2016
- GDPR and events. What does the pharma industry need to know?
- Daily Brief: Limited NICE recommendation for Fasenra, Urovant takes aim at an IPO, Xtandi expands use
- ‘Common Rulebook’ Brexit plans include medicines – but face backlash
- MaxCyte gets green light for solid tumour cell therapy
- Novartis rejects claims it misled Senate over Cohen links
- May’s Brexit plan cautiously welcomed by biopharma sector
PMHub
COUCH.
WE ARE COUCH – a full service medical communications agency. We are a trusted partner; always striving to help make...
Latest intelligence
- GDPR and events. What does the pharma industry need to know?
- ...
- Digital trends in B2B sales - how far behind is Pharma?
- The modern approach to B2B sales is data-driven, and enabled by digital tools....
- The rise of vertical integration in the US payer landscape
- Is it a solution to addressing the challenges of the value-based marketplace?...
Quick links
Infographics
